셀트리온 제약

■ During the last 57 months, since Jun 2017, we have sincerely participated in the audit conducted by the financial authorities on its financial statements for 12 fiscal years. We have faithfully explained our position on the issues raised during this audit. As the decisions announced by Securities & Futures Commission (SFC) on Mar 11, 2022, officially mark the finalization of this audit, we believe that these decisions eliminate a significant portion of the uncertainty about Celltrion Pharms that has existed in the financial market for a long time. These decisions also clear up some of the misunderstandings caused by the differences in opinion between the financial authorities and Celltrion Pharms. ■ It is unfortunate that SFC has found some of our accounting practices in violation of the accounting standards. While we believe that these findings were caused by the different views on how the unique nature of biopharmaceuticals and the relevant international rules are incorporated into our accounting exercises, we respectfully accept SFC’s decisions. ■ The accounting practices that were viewed as violations of the accounting standards occurred in the past, hence having no impact on our current financial statements. ■ With the audit inspection finally resolved, we and the affiliates of Celltrion Group will remain committed to our key business to meet the market and shareholder expectations.  

Regarding the recent news article about the Financial Services Commission’s audit inspection, Celltrion Group would like to state the following:  ■ Celltrion Group learned that a daily newspaper had published an article about some matters pertaining to the progress of the ongoing audit inspection by the financial regulators.  ■ Some information contained in the article does not fully reflect the truth. As the audit inspection is still ongoing, no conclusion has been drawn at this stage.  ■ Celltrion Group has sincerely explained its position so far and will continue to do so in full compliance with the audit inspection process. 

■ Celltrion Group was among the first that have embarked on the development of a therapeutic antibody treatment and a diagnostic kit on the onset of the global spread of the novel coronavirus, in a bid to contribute to stopping what would escalate into the coronavirus pandemic. ■ As Celltrion Group Chairman Seo Jung-jin has said earlier, the development of these solutions is driven by our commitment to placing the public interest before our own. Simply put, we are acting on our responsibility as a faithful member of the global pharmaceutical community as we willingly step forward to help address the global coronavirus pandemic. ■ Our researchers are working round the clock to contribute to the world’s common battle to defeat the COVID-19 pandemic. We ensure that any significant progress is promptly, and transparently, shared with the world, because we would like to give the people a sense of hope that we are moving towards an end of these difficult times. ■ We advise our investors to understand that our efforts to develop a coronavirus treatment and a diagnostic kit are not commercially motivated, and their investment decisions should be made based on our business records and the underlying value of our product portfolio. ■ Leading the global antibody biosimilar market, we have been growing continuously on the back of our robust fundamentals. With the successful development and global launches of monoclonal antibody biopharmaceuticals such as Remsima, Truxima, Herzuma, and Remsima SC, Celltrion is becoming a global pharmaceutical corporation representing South Korea. ■ We ask for your continued interest in our vision for future growth as we continue to build upon our own technological capabilities and R&D know-how.